Earnings ·
Vicore Pharma reports Q3 loss of SEK 124.3M as ASPIRE trial continues
VCREVicore Pharma Holding AB
Vicore Pharma Holding AB reported a third-quarter net loss of SEK 124.3 million (SEK 0.44 per share) for the period ended September 30, 2026, compared to a loss of SEK 113.5 million in the prior-year period. Net revenues were SEK 0.6 million, down from SEK 0.8 million. The company's cash and short-term investments stood at SEK 772.0 million (USD 77.4 million). Key operational updates include the appointment of Rob Slack as Chief Scientific Officer in July and the commencement of U.S. trading on Nasdaq under ticker VCRE. Additionally, an independent Data Monitoring Committee recommended that the Phase 2b ASPIRE trial for buloxibutid continue without modification following a pre-planned futility analysis, with topline results expected in mid-2027. Vicore Pharma is a clinical-stage biopharmaceutical company developing angiotensin II type 2 receptor agonists for respiratory and fibrotic diseases.